Anthera Pharmaceuticals (ANTH) Stock Rating Lowered by Zacks Investment Research

Anthera Pharmaceuticals (NASDAQ:ANTH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, May 3rd.

According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “

A number of other equities research analysts have also commented on the stock. ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Jefferies Group reiterated a “hold” rating and set a $0.50 target price on shares of Anthera Pharmaceuticals in a research report on Thursday, March 15th. Piper Jaffray downgraded shares of Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a report on Monday, March 12th. HC Wainwright restated a “buy” rating on shares of Anthera Pharmaceuticals in a report on Tuesday, March 6th. Finally, Roth Capital initiated coverage on shares of Anthera Pharmaceuticals in a report on Wednesday, February 21st. They set a “buy” rating and a $10.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $3.44.

Anthera Pharmaceuticals remained flat at $$0.29 during midday trading on Thursday, Marketbeat reports. 503,820 shares of the company’s stock traded hands, compared to its average volume of 617,996. Anthera Pharmaceuticals has a twelve month low of $0.27 and a twelve month high of $2.97.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.09. equities analysts expect that Anthera Pharmaceuticals will post -2.28 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of ANTH. Armistice Capital LLC bought a new position in Anthera Pharmaceuticals during the fourth quarter valued at about $1,269,000. 683 Capital Management LLC purchased a new stake in Anthera Pharmaceuticals in the fourth quarter valued at approximately $399,000. Finally, BVF Inc. IL raised its stake in Anthera Pharmaceuticals by 20.9% in the fourth quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock valued at $2,007,000 after purchasing an additional 209,896 shares in the last quarter. Institutional investors own 11.08% of the company’s stock.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.

Get a free copy of the Zacks research report on Anthera Pharmaceuticals (ANTH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply